Ask a research question about Cushing's Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Cushing's Syndrome
creation_date: '2026-01-09T07:21:01Z'
updated_date: '2026-01-09T07:21:01Z'
category: Complex
disease_term:
preferred_term: Cushing syndrome
term:
id: MONDO:0018912
label: Cushing syndrome
parents:
- Endocrine Disorders
- Adrenal Gland Diseases
pathophysiology:
- name: Chronic Cortisol Excess
description: >
Cushing's syndrome results from prolonged exposure to excess glucocorticoids,
either exogenous (iatrogenic from corticosteroid therapy) or endogenous (from
pituitary adenomas secreting ACTH, adrenal tumors, or ectopic ACTH production).
Elevated cortisol causes widespread metabolic, immunologic, and cardiovascular
effects.
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome is defined as a prolonged increase in plasma cortisol levels that is not due to a physiological etiology."
explanation: "This review confirms the fundamental pathophysiology of Cushing's syndrome as prolonged cortisol excess."
biological_processes:
- preferred_term: glucocorticoid secretion
term:
id: GO:0035933
label: glucocorticoid secretion
cell_types:
- preferred_term: glucocorticoid secreting cell
term:
id: CL:0000460
label: glucocorticoid secreting cell
- name: Hypothalamic-Pituitary-Adrenal Axis Dysregulation
description: >
In endogenous Cushing's, the normal negative feedback regulation of cortisol
on the HPA axis is disrupted. ACTH-dependent forms involve autonomous ACTH
secretion from pituitary or ectopic sources, while ACTH-independent forms
involve autonomous adrenal cortisol production bypassing normal regulation.
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing disease, in which corticotropin excess is produced by a benign pituitary tumor, occurs in approximately 60% to 70% of patients with Cushing syndrome due to endogenous cortisol production."
explanation: "This confirms that ACTH-secreting pituitary tumors are the most common cause of endogenous Cushing's, representing HPA axis dysregulation."
cell_types:
- preferred_term: corticotroph
term:
id: CL:0002309
label: corticotroph
- name: Metabolic Consequences of Hypercortisolism
description: >
Chronic cortisol excess induces insulin resistance, hepatic gluconeogenesis,
protein catabolism in muscle and skin, redistribution of adipose tissue to
central deposits, and altered lipid metabolism, leading to the characteristic
phenotypic features of the syndrome.
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome is associated with hyperglycemia, protein catabolism, immunosuppression, hypertension, weight gain, neurocognitive changes, and mood disorders."
explanation: "This confirms the metabolic consequences including hyperglycemia, protein catabolism, and weight gain."
biological_processes:
- preferred_term: response to glucocorticoid
term:
id: GO:0051384
label: response to glucocorticoid
phenotypes:
- name: Central Obesity
description: >
Preferential fat deposition in the trunk, face (moon facies), and dorsocervical
area (buffalo hump) with relative sparing of the extremities, characteristic
of hypercortisolism.
phenotype_term:
preferred_term: truncal obesity
term:
id: HP:0001956
label: Truncal obesity
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and purple striae and with metabolic manifestations such as hyperglycemia, hypertension, and excess fat deposition in the face, back of the neck, and visceral organs."
explanation: "This confirms central obesity with excess fat in the face, back of neck (buffalo hump), and visceral organs."
- name: Purple Striae
description: >
Wide (greater than 1 cm), violaceous stretch marks, typically on the abdomen,
thighs, and upper arms, resulting from cortisol-induced collagen breakdown
and skin thinning.
phenotype_term:
preferred_term: striae distensae
term:
id: HP:0001065
label: Striae distensae
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and purple striae"
explanation: "This confirms purple striae as a characteristic skin manifestation."
- name: Proximal Muscle Weakness
description: >
Progressive weakness and wasting of proximal muscles, particularly of the
lower extremities and pelvic girdle, due to cortisol-induced protein
catabolism and myopathy.
phenotype_term:
preferred_term: proximal muscle weakness
term:
id: HP:0003701
label: Proximal muscle weakness
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome is associated with hyperglycemia, protein catabolism, immunosuppression, hypertension, weight gain, neurocognitive changes, and mood disorders."
explanation: "Protein catabolism from cortisol excess causes proximal muscle weakness and myopathy."
- name: Hypertension
description: >
Elevated blood pressure occurring in the majority of patients, resulting from
cortisol's mineralocorticoid effects on sodium retention and vascular reactivity.
phenotype_term:
preferred_term: hypertension
term:
id: HP:0000822
label: Hypertension
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and purple striae and with metabolic manifestations such as hyperglycemia, hypertension, and excess fat deposition"
explanation: "This confirms hypertension as a characteristic metabolic manifestation."
- name: Glucose Intolerance
description: >
Impaired glucose tolerance or overt diabetes mellitus due to cortisol-induced
insulin resistance and increased hepatic gluconeogenesis.
phenotype_term:
preferred_term: glucose intolerance
term:
id: HP:0001952
label: Glucose intolerance
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome is associated with hyperglycemia, protein catabolism, immunosuppression, hypertension, weight gain, neurocognitive changes, and mood disorders."
explanation: "Hyperglycemia from cortisol-induced insulin resistance is a key feature."
- name: Osteoporosis
description: >
Decreased bone mineral density and increased fracture risk due to cortisol's
inhibitory effects on osteoblast function, calcium absorption, and increased
bone resorption.
phenotype_term:
preferred_term: osteoporosis
term:
id: HP:0000939
label: Osteoporosis
- name: Easy Bruising
description: >
Increased skin fragility and easy bruising resulting from cortisol-induced
loss of subcutaneous connective tissue and capillary fragility.
phenotype_term:
preferred_term: bruising susceptibility
term:
id: HP:0000978
label: Bruising susceptibility
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Cushing syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and purple striae"
explanation: "Easy bruising is confirmed as a characteristic skin change."
treatments:
- name: Surgical Resection
description: >
First-line treatment for most endogenous Cushing's syndrome: transsphenoidal
surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal
tumors, or resection of ectopic ACTH-secreting tumors.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "Management of Cushing syndrome begins with surgery to remove the source of excess endogenous cortisol production"
explanation: "Surgery is confirmed as the first-line treatment for endogenous Cushing's syndrome."
- name: Medical Therapy
description: >
Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or
glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism
when surgery is not possible or has failed.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "medication that includes adrenal steroidogenesis inhibitors, pituitary-targeted drugs, or glucocorticoid receptor blockers"
explanation: "Multiple medication classes are used for hypercortisolism management."
- name: Radiation Therapy
description: >
Pituitary radiation (conventional or stereotactic radiosurgery) for persistent
or recurrent Cushing's disease after unsuccessful surgery.
treatment_term:
preferred_term: radiation therapy
term:
id: MAXO:0000014
label: radiation therapy
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."
explanation: "Radiation therapy is confirmed as an option for refractory cases."
- name: Bilateral Adrenalectomy
description: >
Definitive treatment option for patients with persistent hypercortisolism,
resulting in permanent adrenal insufficiency requiring lifelong hormone
replacement.
treatment_term:
preferred_term: adrenalectomy
term:
id: MAXO:0001030
label: adrenalectomy
evidence:
- reference: PMID:37432427
reference_title: "Cushing Syndrome: A Review."
supports: SUPPORT
snippet: "For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate."
explanation: "Bilateral adrenalectomy is confirmed as a treatment for refractory cases."
datasets:
Cushing’s syndrome is defined as a “prolonged increase in plasma cortisol levels that is not due to a physiological etiology.” (Reincke & Fleseriu, JAMA, published 2023-07, URL: https://doi.org/10.1001/jama.2023.11305) (reincke2023cushingsyndromea pages 1-2)
Only identifiers explicitly available in the retrieved evidence are included here.
| Concept | Definition (1-line) | Common synonyms | Key codes/IDs | Key citation |
|---|---|---|---|---|
| Cushing's syndrome | Prolonged increase in plasma cortisol not due to a physiological etiology; overall most commonly caused by exogenous glucocorticoid exposure. | CS; hypercortisolism; Cushing syndrome | MONDO:0018912 | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3) |
| Endogenous Cushing's syndrome | Cushing's syndrome caused by endogenous overproduction of cortisol rather than exogenous steroids. | endogenous CS; endogenous hypercortisolism | NA | (reincke2023cushingsyndromea pages 1-2, m.c.2025hypertensionandcushing’s pages 1-2) |
| Cushing disease | ACTH-dependent endogenous Cushing syndrome caused by an ACTH-secreting pituitary adenoma/corticotrophinoma. | pituitary Cushing; pituitary ACTH-dependent Cushing syndrome; CD | NA | (reincke2023cushingsyndromea pages 1-2, loughrey2024insightsonepidemiology pages 1-2) |
| Ectopic ACTH syndrome | ACTH-dependent Cushing syndrome caused by non-pituitary ACTH-secreting tumors. | ectopic Cushing syndrome; ectopic ACTH-dependent Cushing syndrome; EAS | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3) |
| Adrenal Cushing | ACTH-independent Cushing syndrome due to autonomous adrenal cortisol production from adrenal tumors or hyperplasia. | adrenal Cushing syndrome; ACTH-independent Cushing syndrome; adrenal hypercortisolism | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3) |
Table: This table summarizes the core disease concept and major clinical subtypes of Cushing's syndrome, with concise definitions, common synonyms, and only those IDs explicitly supported in the available evidence. It is useful for knowledge-base normalization and concept mapping without introducing unsupported coding terms.
Notes on missing identifiers: ICD-10/ICD-11 codes, MeSH IDs, OMIM/Orphanet identifiers were not extractable from the retrieved full-text evidence in this run and are therefore not reported.
The synthesis below draws predominantly from: - Aggregated disease-level resources (high-citation review and cohorts) (reincke2023cushingsyndromea pages 1-2, loughrey2024insightsonepidemiology pages 1-2) - Registry/cohort observational studies (human clinical) (loughrey2024insightsonepidemiology pages 1-2) - Interventional and real-world pharmacotherapy studies (human clinical) (gadelha2023longtermefficacyand pages 1-2, feelders2023longtermefficacyand pages 1-2) - Systematic review evidence for iatrogenic pediatric CS (human clinical) (abdalla2024cushingssyndromeand pages 1-2)
Endogenous CS etiologic distribution (current clinical framing): - ACTH-dependent (pituitary) Cushing disease: ~60–70% of endogenous CS (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3) - ACTH-independent adrenal cortisol production: ~20–30% (reincke2023cushingsyndromea pages 2-3) - Ectopic ACTH-dependent CS: ~6–10% (reincke2023cushingsyndromea pages 2-3)
Key mechanistic statement (authoritative review): evaluation “begins with ruling out exogenous steroid use.” (reincke2023cushingsyndromea pages 1-2)
Clinical risk enrichment groups (examples): In the context of hypertension work-up, a targeted screening phenotype includes younger age (<40 years), rapidly evolving hypertension, adrenal adenomas/incidentalomas, or pituitary lesions. (De Martino et al., J Endocrinol Invest, published 2025-03, URL: https://doi.org/10.1007/s40618-024-02453-9) (m.c.2025hypertensionandcushing’s pages 1-2)
No protective genetic or environmental factors were identified in the retrieved evidence for CS.
A dominant “environmental” driver of CS is exogenous glucocorticoid exposure, including non-oral routes; prevention therefore includes correct prescribing/monitoring and avoiding unrecognized exposure sources. (reincke2023cushingsyndromea pages 1-2, abdalla2024cushingssyndromeand pages 1-2)
CS presents with a multisystem phenotype combining: - Cutaneous findings (e.g., facial plethora, easy bruising, purple striae) (reincke2023cushingsyndromea pages 1-2) - Cardiometabolic findings (e.g., hypertension, hyperglycemia/diabetes, dyslipidemia, central adiposity) (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 4-5) - Neuropsychiatric manifestations (neurocognitive changes, mood disorders) (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 3-4) - Muscle/bone catabolism (proximal weakness, osteopenia/osteoporosis) (reincke2023cushingsyndromea pages 3-4)
The 2023 JAMA review reports a range of symptom frequencies (e.g., weight gain 70–95%, hypertension 60–90%, depression 50–80%, hirsutism 50–75%; purple striae <50%), emphasizing that no single symptom is pathognomonic. (reincke2023cushingsyndromea pages 4-5, reincke2023cushingsyndromea pages 3-4)
| Feature (plain language) | Suggested HPO term (ID and label) | Frequency/notes | Evidence citation |
|---|---|---|---|
| Recent weight gain / central weight gain | HP:0001824 Weight gain | Reported in 70–95% of patients with endogenous Cushing syndrome; often accompanies central fat redistribution | (reincke2023cushingsyndromea pages 3-4) |
| Facial plethora | HP:0012368 Facial plethora | Reported in 70–90%; one of the more characteristic cutaneous signs | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 1-2) |
| High blood pressure | HP:0000822 Hypertension | Reported in 60–90% in JAMA review; other review notes hypertension around 80% overall in endogenous CS | (reincke2023cushingsyndromea pages 3-4, m.c.2025hypertensionandcushing’s pages 1-2) |
| Depression / depressed mood | HP:0000716 Depression | Reported in 50–80%; mood disorders are part of the neuropsychiatric burden | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 1-2) |
| Excess body/facial hair in women | HP:0001007 Hirsutism | Reported in 50–75% | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 4-5) |
| Proximal muscle weakness / myopathy | HP:0003701 Proximal muscle weakness | Reported in 60–80%; reflects protein catabolism and muscle wasting | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 9-10) |
| Round face / moon face | HP:0000340 Round face | Reported in up to 90% | (reincke2023cushingsyndromea pages 3-4) |
| Dorsocervical fat pad (“buffalo hump”) | HP:0030867 Dorsocervical fat pad | Approximately 50% | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 4-5) |
| Purple/violaceous striae | HP:0033677 Abdominal striae | Reported in less than 50%; highly suggestive when wide and violaceous | (reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 1-2) |
| Easy bruising | HP:0000978 Easy bruising | Approximately 50% | (reincke2023cushingsyndromea pages 4-5, reincke2023cushingsyndromea pages 1-2) |
| Thin skin / skin atrophy | HP:0000963 Thin skin | Approximately 40% | (reincke2023cushingsyndromea pages 4-5) |
| Oligomenorrhea or amenorrhea | HP:0000858 Menstrual irregularity | Reported in 70–80% of affected women in JAMA review | (reincke2023cushingsyndromea pages 3-4) |
| Osteopenia / osteoporosis / bone fragility | HP:0000939 Osteoporosis | Reported in up to 80%; fracture burden is substantial in overt CS | (reincke2023cushingsyndromea pages 3-4) |
| Diabetes / hyperglycemia | HP:0005978 Hyperglycemia | Diabetes reported in about 30%; hyperglycemia is a common metabolic manifestation | (reincke2023cushingsyndromea pages 4-5, reincke2023cushingsyndromea pages 1-2) |
| Dyslipidemia | HP:0003119 Hypercholesterolemia | Reported in 40–70%; contributes to cardiometabolic risk | (reincke2023cushingsyndromea pages 4-5) |
| Sleep disturbance | HP:0002360 Sleep disturbance | Approximately 60% | (reincke2023cushingsyndromea pages 4-5) |
| Reduced libido | HP:0012873 Decreased libido | Reported in 25–90%; broad range reflects ascertainment variability | (reincke2023cushingsyndromea pages 4-5) |
| Acne | HP:0001061 Acne | Reported in less than 50% | (reincke2023cushingsyndromea pages 4-5) |
| Kidney stones | HP:0000787 Nephrolithiasis | Reported in up to 50% | (reincke2023cushingsyndromea pages 4-5) |
| Hypokalemia | HP:0002900 Hypokalemia | Common laboratory abnormality; especially prominent in ectopic ACTH syndrome | (stachowska2020etiologybaselineclinical pages 1-2, reincke2023cushingsyndromea pages 1-2) |
Table: This table maps major clinical features of Cushing syndrome to suggested Human Phenotype Ontology terms, with frequency ranges drawn from the 2023 JAMA review and supporting recent evidence. It is useful for structuring phenotype annotations in a disease knowledge base.
Typical laboratory abnormalities include hyperglycemia/insulin changes, dyslipidemia, leukocytosis with relative lymphopenia, and hypokalemia (especially prominent in ectopic ACTH syndrome). (reincke2023cushingsyndromea pages 4-5, stachowska2020etiologybaselineclinical pages 1-2)
While QoL is widely recognized as impaired in CS and treatment trials include patient-reported outcomes, quantitative QoL instrument values (e.g., SF-36, CushingQoL) were not extractable from the retrieved evidence excerpts in this run. Trials and extension studies explicitly track HRQoL as outcomes. (gadelha2023longtermefficacyand pages 1-2)
CS is often tumor-driven and therefore commonly involves somatic drivers (pituitary or adrenal lesions), but several germline syndromic etiologies exist.
| Etiology category | Typical source lesion | Approx proportion | Key genes/variants (somatic vs germline) | Key pathways | Evidence citation |
|---|---|---|---|---|---|
| Pituitary ACTH-dependent Cushing disease | ACTH-secreting pituitary corticotroph adenoma / corticotrophinoma | ~60–70% of endogenous CS; registry example 64% | USP8 somatic activating variants are the most common genetic defect in corticotroph tumors; reported in ~35–41% overall, enriched in females. Other less common somatic alterations in corticotroph tumors: USP48 (~6%), TP53 (rare, associated with aggressive tumors/poor outcome), rare BRAF reports; germline defects linked to some cases include MEN1, CDKN1B, DICER1 | EGFR/MAPK activation downstream of USP8; altered somatostatin receptor trafficking/signaling; pituitary tumorigenesis pathways | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3, reincke2023cushingsyndromea pages 3-4, loughrey2024insightsonepidemiology pages 1-2, reincke2023cushingsyndromea pages 9-10) |
| Ectopic ACTH-dependent Cushing syndrome | Non-pituitary ACTH-secreting tumors, especially lung carcinoids/small cell and other neuroendocrine tumors | ~6–10% (review); single-center cohort ~11% | No recurrent single germline driver established in provided evidence for all ectopic cases; tumor genetics are heterogeneous and depend on underlying neuroendocrine neoplasm | Ectopic ACTH/CRH secretion driving adrenal cortisol excess | (reincke2023cushingsyndromea pages 2-3, reincke2023cushingsyndromea pages 3-4, stachowska2020etiologybaselineclinical pages 1-2) |
| Adrenal ACTH-independent Cushing syndrome (overall) | Cortisol-producing adrenal adenoma, bilateral adrenal hyperplasia, rare adrenocortical carcinoma | ~20–30% (review); registry example 30%; single-center cohort 25% | Genetic causes vary by lesion type. In cortisol-producing adrenal tumors/hyperplasias, provided evidence supports involvement of PRKACA, PRKAR1A, PDE11A, PDE8B, ARMC5, CTNNB1, GNAS (lesion-specific; somatic and/or germline depending on disorder) | Dysregulated adrenal steroidogenesis, especially cAMP/PKA signaling | (reincke2023cushingsyndromea pages 2-3, reincke2023cushingsyndromea pages 3-4, reincke2023cushingsyndromea pages 8-9) |
| Primary pigmented nodular adrenocortical disease (PPNAD) / micronodular adrenal disease | Bilateral pigmented micronodular adrenal hyperplasia; often Carney complex-associated | Rare adrenal subtype; within reviewed PPNAD cases, 31.43% had Carney complex | Predominantly PRKAR1A pathogenic variants (most common; 79.47% of genetically tested PPNAD cases in 2024 systematic review), usually germline; additional reported genes in PPNAD/micronodular disease: PDE11A, PRKACA (including germline amplification/copy gain), CTNNB1, PDE8B, ARMC5 | cAMP/PKA pathway dysregulation in adrenal cortex | (reincke2023cushingsyndromea pages 8-9) |
| Primary bilateral macronodular adrenal hyperplasia (PBMAH) / bilateral nodular adrenal disease | Bilateral macronodular adrenal hyperplasia with autonomous cortisol secretion | Rare adrenal subtype | ARMC5 germline mutations reported in 25–50% of PBMAH; additional familial associations noted with APC, MEN1, FH; aberrant GPCR expression also implicated | Aberrant receptor signaling converging on cAMP/PKA | (reincke2023cushingsyndromea pages 8-9) |
| Carney complex-associated adrenal Cushing syndrome | PPNAD in the setting of multisystem Carney complex | Subset of PPNAD; in one review 31.43% of PPNAD cases had Carney complex | PRKAR1A germline inactivating variants are the canonical cause; rare PRKACA constitutional amplification/copy gain also reported in Carney-complex-like PPNAD presentations | cAMP/PKA signaling | (reincke2023cushingsyndromea pages 8-9) |
| Exogenous/iatrogenic Cushing syndrome (not endogenous; important exclusion) | Chronic glucocorticoid exposure by oral, inhaled, topical, ocular, or interacting-drug routes | Most common cause of Cushing syndrome overall, but excluded from endogenous CS classification | Not a primary genetic etiology of endogenous CS; drug interactions can precipitate phenotype | HPA-axis suppression from exogenous glucocorticoids | (reincke2023cushingsyndromea pages 1-2) |
Table: This table summarizes the main endogenous Cushing syndrome etiologies, their approximate frequencies, and the best-supported genes and pathways from the cited evidence. It is useful for linking disease subtypes to lesion source, inheritance context, and molecular mechanisms.
Recent molecular work continues to refine corticotroph tumorigenesis. For example, an analysis/systematic review of USP8 highlights that activating USP8 alterations are implicated in ACTH secretion and cell proliferation in corticotroph adenomas and motivates EGFR and USP8 pathway targeting as a research direction. (Hashemi‑Madani et al., BMC Endocr Disord, published 2024-06, URL: https://doi.org/10.1186/s12902-024-01619-z) (reincke2023cushingsyndromea pages 9-10)
Exogenous glucocorticoids are the most common cause of CS overall, and iatrogenic CS can occur via multiple routes. (reincke2023cushingsyndromea pages 1-2)
A pediatric systematic review of topical corticosteroid-associated iatrogenic CS reported (n=63): 81% recovered, 3.2% partially recovered, and 6.3% died, with a mean exposure duration of 25.4 weeks; discontinuation of the offending steroid was universal, and oral hydrocortisone replacement was commonly used. (Abdalla et al., published 2024-09, URL: https://doi.org/10.58742/bmj.v2i3.104) (abdalla2024cushingssyndromeand pages 1-2)
Excess cortisol can overwhelm 11β-HSD2 protection, allowing mineralocorticoid receptor activation with sodium retention and hypokalemia, and can amplify vascular pressor responses, contributing to the ~80% hypertension prevalence reported in endogenous CS. (m.c.2025hypertensionandcushing’s pages 1-2)
Multiple adrenal etiologies converge on cAMP/PKA signaling dysregulation (e.g., PRKAR1A in PPNAD; ARMC5 in PBMAH; other lesion-specific genes), consistent with endocrine control of adrenal steroidogenesis. (reincke2023cushingsyndromea pages 8-9)
Suggested ontology terms (mechanism; not evidence-derived): - GO:0006954 inflammatory response (downstream infection susceptibility context) - GO:0008283 cell population proliferation (pituitary/adrenal tumor growth) - GO:0010817 regulation of hormone levels
Suggested anatomy ontology terms (not evidence-derived): - UBERON:0000007 pituitary gland - UBERON:0002369 adrenal gland
CS is typically subacute-to-chronic and often underdiagnosed; cohort data highlight diagnostic challenges (e.g., microadenomas frequently occult on imaging). (reincke2023cushingsyndromea pages 2-3, loughrey2024insightsonepidemiology pages 1-2)
After curative treatment, the median time to normalization of the HPA axis differs by etiology: 0.6 years (ectopic), 1.4 years (Cushing disease), 2.5 years (adrenal CS). (reincke2023cushingsyndromea pages 8-9)
While most pituitary/adrenal tumors are sporadic, germline causes are important in specific subtypes: - PPNAD/Carney complex: commonly PRKAR1A germline pathogenic variants (reincke2023cushingsyndromea pages 8-9)
The diagnostic process requires biochemical confirmation; elevated cortisol alone is insufficient and most patients require more than one screening test. The recommended first-line screening tests are: - 24-hour UFC - Late-night salivary cortisol - 1-mg overnight dexamethasone suppression test (DST) with 2–3 samples recommended for UFC and late-night salivary cortisol due to intrapatient variability. (reincke2023cushingsyndromea pages 4-5, reincke2023cushingsyndromea pages 2-3)
After biochemical confirmation, plasma ACTH separates ACTH-independent adrenal causes (suppressed ACTH) from ACTH-dependent causes (midnormal/elevated ACTH). Localization may require pituitary MRI and/or bilateral inferior petrosal sinus sampling (IPSS); these are not screening tools. (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3)
A stepwise diagnostic algorithm for suspected CS, including screening tests and subsequent etiologic classification/localization, is shown in the JAMA review (Figure 2). (reincke2023cushingsyndromea media 4775d5aa)
Assay-specific LNSC cutoffs vary; in one prospective study, a cutoff of 10.1 nmol/L yielded 94% sensitivity and 84% specificity for hypercortisolism. (reincke2023cushingsyndromea pages 4-5)
DST false positives can arise from inadequate dexamethasone exposure; measuring dexamethasone and using method-specific cortisol thresholds improved clinical specificity from 67.5% to 92.4% while preserving 100% sensitivity in one LC–MS/MS-based evaluation. (reincke2023cushingsyndromea pages 4-5)
| Test | Specimen | Purpose (screen vs etiology vs localization) | Notes | Performance metrics if present | Evidence citation |
|---|---|---|---|---|---|
| 24-hour urinary free cortisol (UFC) | 24-hour urine | Screen | One of 3 standard first-line screening tests for suspected hypercortisolism; most patients require more than 1 test; 2-3 samples are recommended because of intrapatient variability | NA in provided evidence | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 4-5, reincke2023cushingsyndromea pages 2-3) |
| Late-night salivary cortisol (LNSC) | Saliva collected late at night | Screen | Noninvasive first-line screening test; 2-3 samples recommended; considered highly discriminatory in selected hypertensive patients | Assay-specific cutoff 10.1 nmol/L with sensitivity 94% and specificity 84% for hypercortisolism; ectopic ACTH-production cutoff 109.0 nmol/L with sensitivity 50% and specificity 92% | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 4-5, m.c.2025hypertensionandcushing’s pages 1-2) |
| 1-mg overnight dexamethasone suppression test (DST) | Serum cortisol after dexamethasone; dexamethasone exposure may also be measured | Screen | Standard first-tier screening test; false positives can occur with missed/insufficient dexamethasone exposure; in adrenal incidentaloma, 1-mg DST is the preferred screening test; post-DST cortisol >50 nmol/L (>1.8 μg/dL) indicates mild autonomous cortisol secretion in 2023 adrenal incidentaloma guidance | Method-specific approach: excluding samples with dexamethasone <1.8 ng/mL and using cortisol cutoff 2.4 μg/dL (66 nmol/L) increased clinical specificity from 67.5% to 92.4% while preserving 100% sensitivity | (reincke2023cushingsyndromea pages 1-2, m.c.2025hypertensionandcushing’s pages 1-2, reincke2023cushingsyndromea pages 2-3) |
| Plasma ACTH | Plasma | Etiology | Used after biochemical confirmation to distinguish adrenal causes (suppressed ACTH) from ACTH-dependent causes (midnormal/elevated ACTH) | Morning ACTH cutoffs referenced in review: <10 pg/mL suggests ACTH-independent; >20 pg/mL suggests ACTH-dependent; 10-20 pg/mL indeterminate | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 4-5) |
| Repeat/confirmatory biochemical testing | Mixed: urine, saliva, serum | Screen / confirmation | Diagnosis requires biochemical confirmation; elevated plasma cortisol alone is insufficient; if initial results are inconclusive, second-line dynamic tests may be used | NA | (reincke2023cushingsyndromea pages 4-5) |
| Desmopressin stimulation test | Blood | Etiology / second-line confirmation | Mentioned as a second-line test when first-line studies are inconclusive | NA | (reincke2023cushingsyndromea pages 4-5) |
| 2-day DST-CRH combined test | Blood | Etiology / second-line confirmation | Mentioned as a second-line test for inconclusive cases and for separating neoplastic hypercortisolism from physiologic/non-neoplastic hypercortisolism | NA | (reincke2023cushingsyndromea pages 4-5) |
| Pituitary MRI | MRI imaging | Localization | Used after biochemical confirmation and ACTH-based classification to identify pituitary source; microadenomas may be occult on MRI in a substantial fraction of Cushing disease cases | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3, loughrey2024insightsonepidemiology pages 1-2, reincke2023cushingsyndromea media 4775d5aa) |
| Bilateral inferior petrosal sinus sampling (IPSS/BIPSS) | Central venous sampling | Localization | Used to distinguish pituitary ACTH secretion from ectopic ACTH secretion after biochemical confirmation; should not be used for screening | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 2-3, loughrey2024insightsonepidemiology pages 1-2, reincke2023cushingsyndromea media 4775d5aa) |
| Adrenal CT/MRI or adrenal imaging | Imaging | Localization | Used when ACTH is suppressed or adrenal source suspected | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea media 4775d5aa) |
| Whole-body imaging for ectopic source | Cross-sectional and/or functional imaging | Localization | Used when ACTH-dependent hypercortisolism is confirmed and pituitary source is not established, to search for ectopic ACTH-producing tumors | NA | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea media 4775d5aa) |
Table: This table summarizes the main diagnostic tests used in Cushing syndrome, separating first-line screening from etiology and localization studies. It also includes assay-specific performance values when they were available in the evidence.
Endogenous CS is associated with persistent excess mortality. A meta-analysis reported standardized mortality ratio (SMR) 3.0 (95% CI 2.3–3.9), and pooled data attribute many deaths to atherosclerotic disease, thromboembolism, and infection. (reincke2023cushingsyndromea pages 9-10)
In a regional neurosurgical cohort of Cushing disease in Northern Ireland, mortality was substantially elevated versus the general population (SMR 8.10, 95% CI 3.3–16.7). (loughrey2024insightsonepidemiology pages 1-2)
Registry data indicate markedly elevated standardized incidence rates for complications in the 3 years before diagnosis, including myocardial infarction, fractures, and deep vein thrombosis (values reported as 4.4, 4.9, and 13.8, respectively). (reincke2023cushingsyndromea pages 9-10)
Recurrence after transsphenoidal surgery for Cushing disease can occur in up to 35% of patients. (reincke2023cushingsyndromea pages 8-9)
For endogenous CS, “first-line therapy… is surgery to remove the underlying tumor”, with additional medical therapy, radiation, or bilateral adrenalectomy used when needed. (reincke2023cushingsyndromea pages 9-10)
| Modality/drug | Mechanism/class | Typical use case | Key quantitative outcomes | Key safety issues | Evidence citation |
|---|---|---|---|---|---|
| Transsphenoidal pituitary surgery | Surgical removal of ACTH-secreting pituitary adenoma | First-line for Cushing disease when lesion is resectable | In a Northern Ireland population-based surgical cohort, immediate postoperative remission was 53% using serum cortisol ≤ 50 nmol/L and 66% using ≤ 138 nmol/L in the first postoperative week; ~70% achieved longer-term remission after a single pituitary surgery | Surgical failure/non-remission; recurrence can occur; requires specialized pituitary center expertise | (loughrey2024insightsonepidemiology pages 1-2, reincke2023cushingsyndromea pages 9-10) |
| Surgery for endogenous Cushing syndrome overall | Surgery to remove causative pituitary, adrenal, or ectopic tumor | First-line therapy for endogenous tumor-driven Cushing syndrome | Authoritative review states first-line therapy is surgery to remove the underlying tumor; many patients subsequently require medication, radiation, or bilateral adrenalectomy | Procedure- and site-specific perioperative risks; persistent disease may require multimodal care | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 9-10) |
| Osilodrostat | Adrenal steroidogenesis inhibitor; oral 11β-hydroxylase (CYP11B1) inhibitor | Persistent/recurrent Cushing disease; bridge or alternative when surgery is not feasible/curative; increasingly used across etiologies in practice | LINC 4 extension: 72.4% had normalized mean urinary free cortisol (mUFC) at end-of-trial; 60 entered extension, 53 completed, median treatment duration 87.1 weeks; real-world ILLUSTRATE: UFC fell below ULN in 14/20 (70.0%) with elevated pretreatment UFC; Spanish real-world cohort: 33/37 (89.2%) complete responders, median time to UFC normalization 4 weeks, and 67% normalized by month 1 | Adrenal insufficiency/hypocortisolism; glucocorticoid withdrawal syndrome/adrenal insufficiency in 12/42 (28.6%) in ILLUSTRATE; edema, fatigue, nausea; QT prolongation risk noted in review literature | (gadelha2023longtermefficacyand pages 1-2, araujocastro2025realworlddataon pages 12-13) |
| Osilodrostat (clinical manifestations data) | Same as above | Longer-term medical control of hypercortisolism with monitoring of biochemical and clinical response | In LINC 3, mUFC was controlled in 67.9% at week 24 and 66.4% at week 48; improvements in cardiometabolic parameters, physical manifestations, and QoL generally accompanied mUFC reduction | Requires dose titration and monitoring for adrenal insufficiency and steroid precursor-related effects | (araujocastro2025realworlddataon pages 12-13) |
| Pasireotide-LAR | Pituitary-directed somatostatin receptor ligand (SSTR-targeted) | Persistent/recurrent Cushing disease, especially when pituitary-directed medical therapy is desired | Real-world 12-month study: sustained mUFC reduction, greatest decline in first 3 months (p=0.007); systolic blood pressure decreased during first 6 months (p=0.005); cited phase 3 benchmark mUFC normalization 41% at month 7 | Hyperglycemia was the most common adverse event; fasting glucose and HbA1c increased, with HbA1c significantly higher at last follow-up (p=0.04) | (dzialach2025realworldexperiencewith pages 1-2) |
| Pasireotide subcutaneous ± cabergoline | Pituitary-directed SRL alone or combined with dopamine agonist | Patients with active Cushing disease not adequately controlled on pasireotide alone | Phase II study: 34/68 (50.0%; 95% CI 37.6–62.4) achieved mUFC ≤ ULN at week 35; control remained stable through week 99; responders split evenly between pasireotide monotherapy (17) and pasireotide+cabergoline (17) | Hyperglycemia 51.5%, nausea 51.5%, diarrhea 44.1%, cholelithiasis 33.8% | (feelders2023longtermefficacyand pages 1-2) |
| Pasireotide real-life monotherapy/combination | Same as above; combination with cabergoline or metyrapone in practice | Real-world escalation strategy when UFC remains elevated on monotherapy | Monotherapy normalized UFC in 59% and LNSC in 38%; adding a second cortisol-lowering agent increased overall UFC normalization to 67%; >5% weight loss in 47%; half showed improved blood-pressure profile | Clinically significant hyperglycemia in 61%; circadian rhythm control remained difficult | (mondin2025reallifedataon pages 1-2) |
| Cabergoline add-on | Dopamine agonist | Add-on to pasireotide in incompletely controlled Cushing disease | In the phase II pasireotide study, cabergoline add-on contributed to the 50% overall week-35 mUFC control rate and sustained control to week 99 in combination-treated patients | Add-on tolerability considered acceptable in study; agent-specific risks not quantified in the provided evidence | (feelders2023longtermefficacyand pages 1-2) |
| Metyrapone add-on | Adrenal steroidogenesis inhibitor (11β-hydroxylase inhibition) | Add-on to pituitary-directed therapy in real-life regimens | In the 2025 real-life pasireotide cohort, add-on therapy (including metyrapone) increased overall UFC normalization from 59% on pasireotide alone to 67% overall | Add-on treatment was described as generally well tolerated in this cohort | (mondin2025reallifedataon pages 1-2) |
| Steroidogenesis inhibitors as a class | Adrenal cortisol synthesis blockade | Alternative to surgery when surgery is infeasible/contraindicated; rapid control for severe hypercortisolism; bridge therapy | 2024 review states these drugs are a therapeutic alternative when surgery is not feasible and are particularly important when rapid cortisol control is needed; evidence base has expanded, but head-to-head comparative studies remain limited | Drug-specific toxicities vary; careful individualized selection and monitoring required | (m.c.2025hypertensionandcushing’s pages 1-2) |
| Radiation therapy / stereotactic radiosurgery | Delayed local pituitary tumor control | Second-line for persistent/recurrent Cushing disease after surgery or with residual tumor | Review reports stereotactic radiation is highly effective (~92%) for tumor control, with 5-year biochemical remission 50%–65% | New hypopituitarism in ~20%; delayed onset of biochemical effect | (reincke2023cushingsyndromea pages 9-10) |
| Bilateral adrenalectomy | Definitive surgical ablation of adrenal cortisol production | Severe persistent hypercortisolism despite other therapy or when rapid normalization is needed | Expert review describes it as an option for patients not responsive to surgery/medication and for urgent cortisol control; specific quantitative outcomes not provided in the available evidence | Lifelong adrenal insufficiency and need for steroid replacement; procedure-related risks | (reincke2023cushingsyndromea pages 1-2, reincke2023cushingsyndromea pages 9-10) |
Table: This table summarizes major treatment modalities for endogenous Cushing syndrome and Cushing disease, including real-world implementation patterns and quantitative outcomes where available. It is useful for comparing first-line surgery with newer medical therapies such as osilodrostat and pasireotide, alongside key safety considerations.
Key recent quantitative examples: - Osilodrostat (LINC 4 extension, 2023): 72.4% achieved normal mean UFC at end-of-trial, with sustained clinical improvements over long-term therapy. (Gadelha et al., published 2023-08, URL: https://doi.org/10.3389/fendo.2023.1236465) (gadelha2023longtermefficacyand pages 1-2) - Pasireotide ± cabergoline (Phase II, 2023): 50.0% achieved mean UFC ≤ ULN at week 35; hyperglycemia occurred in 51.5%. (Feelders et al., published 2023-10, URL: https://doi.org/10.3389/fendo.2023.1165681) (feelders2023longtermefficacyand pages 1-2)
Because exogenous glucocorticoids are the most common overall cause, a core preventive step is to identify and avoid unnecessary glucocorticoid exposure, including non-oral preparations. (reincke2023cushingsyndromea pages 1-2)
In pediatric topical-steroid iatrogenic CS, prevention recommendations include specialist supervision of topical corticosteroid administration and caregiver education on correct use and side effects. (abdalla2024cushingssyndromeand pages 1-2)
Screening is recommended in selected high-risk clinical contexts (e.g., adrenal adenomas; hypertensive patients with red-flag phenotype), using UFC, DST, or LNSC rather than indiscriminate testing. (reincke2023cushingsyndromea pages 2-3, m.c.2025hypertensionandcushing’s pages 1-2)
Veterinary or cross-species data were not retrieved in evidence suitable for synthesis in this run.
Model-organism evidence was not retrieved in evidence suitable for synthesis in this run.
References
(reincke2023cushingsyndromea pages 1-2): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(reincke2023cushingsyndromea pages 2-3): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(m.c.2025hypertensionandcushing’s pages 1-2): De Martino M.C., L. Canu, I. Bonaventura, C. Vitiello, C. Sparano, and A. Cozzolino. Hypertension and cushing’s syndrome: hunt for the red flag. Journal of Endocrinological Investigation, 48:1909-1918, Mar 2025. URL: https://doi.org/10.1007/s40618-024-02453-9, doi:10.1007/s40618-024-02453-9. This article has 6 citations and is from a peer-reviewed journal.
(loughrey2024insightsonepidemiology pages 1-2): Paul Benjamin Loughrey, Brian Herron, Stephen Cooke, Philip Weir, Jayna Elizabeth Smyth, Karen R Mullan, Estelle G Healy, Jane Evanson, Stephanie G Craig, Jacqueline A James, Márta Korbonits, and Steven J Hunter. Insights on epidemiology, morbidity and mortality of cushing’s disease in northern ireland. Endocrine-Related Cancer, Jun 2024. URL: https://doi.org/10.1530/erc-24-0028, doi:10.1530/erc-24-0028. This article has 9 citations and is from a domain leading peer-reviewed journal.
(gadelha2023longtermefficacyand pages 1-2): Mônica Gadelha, Peter J. Snyder, Przemysław Witek, Marie Bex, Zhanna Belaya, Adina F. Turcu, Richard A. Feelders, Anthony P. Heaney, Michaela Paul, Alberto M. Pedroncelli, and Richard J. Auchus. Long-term efficacy and safety of osilodrostat in patients with cushing’s disease: results from the linc 4 study extension. Frontiers in Endocrinology, Aug 2023. URL: https://doi.org/10.3389/fendo.2023.1236465, doi:10.3389/fendo.2023.1236465. This article has 44 citations.
(feelders2023longtermefficacyand pages 1-2): Richard A. Feelders, Maria Fleseriu, Pinar Kadioglu, Marie Bex, Deyanira González-Devia, Cesar Luiz Boguszewski, Dilek Gogas Yavuz, Heather Patino, Alberto M. Pedroncelli, Ricardo Maamari, Arghya Chattopadhyay, Beverly M. K. Biller, and Rosario Pivonello. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in cushing’s disease. Frontiers in Endocrinology, Oct 2023. URL: https://doi.org/10.3389/fendo.2023.1165681, doi:10.3389/fendo.2023.1165681. This article has 26 citations.
(abdalla2024cushingssyndromeand pages 1-2): Berun A. Abdalla, Maria A. Rasool, Goran J. Baiz, Zanyar Kh. Hama, Karokh K. Mohammed, Yousif M. Mahmood, Ronak S. Ahmed, Wirya N. Sabr, Khdir Hussein Hamad Khoshnaw, Soran M. Ahmed, Karzan M. Hasan, Bilal A. Mohammed, Honar O. Kareem, and Dyari Q. Hamad. Cushing's syndrome and topical corticosteroids in pediatrics: a systematic review. Barw Medical Journal, Sep 2024. URL: https://doi.org/10.58742/bmj.v2i3.104, doi:10.58742/bmj.v2i3.104. This article has 3 citations.
(reincke2023cushingsyndromea pages 4-5): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(reincke2023cushingsyndromea pages 3-4): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(reincke2023cushingsyndromea pages 9-10): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(stachowska2020etiologybaselineclinical pages 1-2): Barbara Stachowska, Justyna Kuliczkowska-Płaksej, Marcin Kałużny, Jędrzej Grzegrzółka, Maja Jończyk, and Marek Bolanowski. Etiology, baseline clinical profile and comorbidities of patients with cushing’s syndrome at a single endocrinological center. Endocrine, 70:616-628, Sep 2020. URL: https://doi.org/10.1007/s12020-020-02468-1, doi:10.1007/s12020-020-02468-1. This article has 9 citations and is from a peer-reviewed journal.
(reincke2023cushingsyndromea pages 8-9): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(stachowska2020etiologybaselineclinical pages 11-12): Barbara Stachowska, Justyna Kuliczkowska-Płaksej, Marcin Kałużny, Jędrzej Grzegrzółka, Maja Jończyk, and Marek Bolanowski. Etiology, baseline clinical profile and comorbidities of patients with cushing’s syndrome at a single endocrinological center. Endocrine, 70:616-628, Sep 2020. URL: https://doi.org/10.1007/s12020-020-02468-1, doi:10.1007/s12020-020-02468-1. This article has 9 citations and is from a peer-reviewed journal.
(reincke2023cushingsyndromea media 4775d5aa): Martin Reincke and Maria Fleseriu. Cushing syndrome: a review. JAMA, 330 2:170-181, Jul 2023. URL: https://doi.org/10.1001/jama.2023.11305, doi:10.1001/jama.2023.11305. This article has 229 citations.
(araujocastro2025realworlddataon pages 12-13): Marta Araujo-Castro, Rogelio García-Centeno, Laura González, Felicia A. Hanzu, Aida Orois, Rosa Camara, María Dolores Ollero García, Ana Irigaray Echarri, Paola Gracia Gimeno, Eider Pascual-Corrales, Betina Biagetti, Andrés Cardona, Inmaculada González Molero, Andreu Simo-Servat, Fernando Guerrero Pérez, Rocío Villar-Taibo, Ignacio Bernabéu, Carmen Fajardo-Montañana, Cristina Novo-Rodríguez, Carmen Tenorio Jimenéz, María Calatayud, María Dolores Moure Rodríguez, Fernando Cordido, Ana Castro, Lucía Manzano Valero, Miguel Paja Fano, Jessica Goi, Anna Aulinas, Pablo Abellán, Pedro Iglesias, and Alfonso Soto-Moreno. Real-world data on the efficacy and safety of osilodrostat in patients with cushing’s disease in spain. Journal of Clinical Medicine, 14:7575, Oct 2025. URL: https://doi.org/10.3390/jcm14217575, doi:10.3390/jcm14217575. This article has 2 citations.
(dzialach2025realworldexperiencewith pages 1-2): Lukasz Dzialach, Wioleta Respondek, and Przemyslaw Witek. Real-world experience with pasireotide-lar in cushing’s disease: single-center 12-month observational study. Journal of Clinical Medicine, 14:2794, Apr 2025. URL: https://doi.org/10.3390/jcm14082794, doi:10.3390/jcm14082794. This article has 3 citations.
(mondin2025reallifedataon pages 1-2): Alessandro Mondin, Filippo Ceccato, Carla Scaroni, Luca Denaro, Renzo Manara, Umberto Maria Robertazzo, and Mattia Barbot. Real-life data on pasireotide in monotherapy or combined in active cushing’s disease. Frontiers in Endocrinology, Nov 2025. URL: https://doi.org/10.3389/fendo.2025.1695342, doi:10.3389/fendo.2025.1695342. This article has 0 citations.